Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. It is crucial for clinicians to exercise independent medical judgment, consider individual patient circumstances, and consult the latest evidence-based guidelines and expert consensus. Drug dosages and treatment regimens should always be verified against official prescribing information and adapted to the patient's specific condition, comorbidities, and local protocols. This document is not a substitute for direct patient care, consultation with specialists, or thorough clinical evaluation.

Acute Encephalitis Syndrome

Overview

• Definition: Acute Encephalitis Syndrome (AES) is a clinical syndrome characterized by acute onset of fever, along with altered mental status (e.g., confusion, disorientation, somnolence, coma), seizures, or focal neurological signs. It signifies acute inflammation of the brain parenchyma, most commonly caused by viral infections, but can also result from bacterial, fungal, parasitic, or autoimmune etiologies.
• Epidemiology:
  • Global Incidence: Highly variable, estimated at 3.5 to 7.4 per 100,000 person-years. Incidence is higher in children and the elderly.
  • Regional Variations: Geographic distribution varies significantly with the prevalence of specific pathogens.
    • Japanese Encephalitis (JE): Endemic in Southeast Asia, East Asia, and parts of the Pacific. A major cause of AES in these regions.
    • West Nile Virus (WNV): Predominant cause of arboviral encephalitis in North America.
    • Herpes Simplex Virus (HSV-1): The most common cause of sporadic, severe fatal encephalitis globally, accounting for 10-20% of cases.
    • Enteroviruses: Common cause in children.
    • Tick-borne encephalitis (TBE): Endemic in parts of Europe and Asia.
  • Seasonality: Varies with vector-borne diseases (e.g., arboviruses are seasonal, peaking in warmer months) while others (e.g., HSV) occur year-round.
  • Demographics: Extremes of age (very young and very old) are at higher risk for severe disease and adverse outcomes. Immunocompromised individuals are also at increased risk.
• Classification:
  • Infectious Encephalitis:
    • Viral (most common): Herpesviruses (HSV-1, HSV-2, VZV, CMV, HHV-6, EBV), Arboviruses (WNV, JE, TBE, St. Louis Encephalitis, Eastern/Western Equine Encephalitis, Chikungunya, Zika), Enteroviruses, Measles, Mumps, Influenza, Rabies, La Crosse virus.
    • Bacterial: Rarely a direct cause of encephalitis, more often causes meningoencephalitis (e.g., Listeria monocytogenes, Mycobacterium tuberculosis, Borrelia burgdorferi (Lyme disease), Mycoplasma pneumoniae).
    • Fungal: Cryptococcus neoformans, Coccidioides immitis, Histoplasma capsulatum, Candida species (often in immunocompromised).
    • Parasitic: Toxoplasma gondii (immunocompromised), Naegleria fowleri (primary amoebic meningoencephalitis), Plasmodium falciparum (cerebral malaria), Taenia solium (neurocysticercosis).
  • Autoimmune Encephalitis: A rapidly growing category, where the immune system attacks brain components.
    • Antibody-mediated: Anti-NMDA receptor, anti-LGI1, anti-CASPR2, anti-GABA-B receptor, anti-AMPAR.
    • Paraneoplastic: Often associated with underlying malignancy (e.g., small cell lung cancer, teratomas).
    • Post-infectious: Acute disseminated encephalomyelitis (ADEM), typically following viral infection or vaccination.
  • Other/Undetermined Causes: A significant proportion of encephalitis cases remain idiopathic despite extensive investigation.

Pathophysiology

• Mechanism:
  • Infectious: Pathogens typically enter the central nervous system (CNS) via hematogenous spread (crossing the blood-brain barrier) or by retrograde axonal transport (e.g., HSV, rabies). Once in the brain parenchyma, they replicate within neurons or glial cells, leading to direct cytopathic effects, inflammation, and immune-mediated damage. This results in neuronal dysfunction, edema (vasogenic and cytotoxic), microglial activation, and sometimes vasculitis. The specific neurotropism of viruses dictates the affected brain regions (e.g., HSV-1 often targets temporal lobes, WNV basal ganglia).
  • Autoimmune: Characterized by autoantibodies targeting neuronal surface antigens, synaptic proteins, or intracellular antigens. These antibodies or T-cell mediated responses disrupt synaptic function, neuronal excitability, or cause direct neuronal damage, leading to inflammation and neurological deficits. The damage can be reversible if treated early.
• Risk Factors:
  • Immunosuppression: HIV/AIDS, organ transplantation, chemotherapy, chronic corticosteroid use (increases risk for opportunistic infections like CMV, toxoplasmosis, fungal infections).
  • Age Extremes: Infants, young children, and elderly individuals have less robust or waning immune systems, increasing susceptibility and severity.
  • Geographic Exposure/Travel: Endemic areas for arboviruses (e.g., JE in Asia, WNV in North America), Lyme disease (tick-borne areas).
  • Lack of Vaccination: Unvaccinated individuals are at risk for vaccine-preventable causes (e.g., measles, mumps, JE, TBE, rabies).
  • Environmental Exposure: Mosquito and tick bites (arboviruses, TBE, Lyme), animal contact (rabies), contaminated water (Naegleria).
  • Underlying Malignancy: Associated with paraneoplastic autoimmune encephalitides.
• Protective Factors:
  • Vaccination: Effective vaccines against JE, MMR, VZV, TBE, rabies, influenza significantly reduce incidence.
  • Vector Control: Mosquito control programs, use of insect repellents (DEET, picaridin), protective clothing, bed nets to prevent arboviral infections.
  • Hygiene: Handwashing, safe food and water practices.
  • Prompt Diagnosis and Treatment: Early initiation of specific antiviral therapy (e.g., acyclovir for HSV) significantly reduces morbidity and mortality.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: The core triad of AES:
  • Fever: Typically acute onset, often high-grade.
  • Headache: Usually diffuse, severe, and persistent.
  • Altered Mental Status: Ranges from subtle confusion, disorientation, irritability, and lethargy to profound somnolence or coma. This is the defining feature distinguishing encephalitis from meningitis alone.
  • Seizures: Occur in up to 60% of cases, can be focal or generalized, or status epilepticus.
  • Focal Neurological Deficits: Hemiparesis, cranial nerve palsies, aphasia, ataxia, movement disorders (e.g., chorea, dystonia in WNV, basal ganglia involvement).
• Early Signs:
  • Prodromal phase (days before acute onset) with flu-like symptoms: malaise, myalgia, fatigue, nausea, vomiting, mild upper respiratory symptoms.
  • Subtle changes in behavior, personality, or judgment.
  • Mild confusion or difficulty concentrating.
• Advanced Signs:
  • Deep coma (GCS ≤ 8), requiring mechanical ventilation.
  • Signs of increased intracranial pressure (ICP): Papilledema, Cushing's triad (hypertension, bradycardia, irregular respirations), pupillary changes (fixed, dilated pupils).
  • Decorticate or decerebrate posturing.
  • Severe autonomic dysfunction (e.g., cardiac arrhythmias, blood pressure lability).
  • Status epilepticus.
• Atypical Presentations:
  • Psychiatric Predominance: Prominent psychiatric symptoms like psychosis, agitation, or severe behavioral changes can be the presenting features, especially in autoimmune encephalitis (e.g., anti-NMDA receptor encephalitis).
  • Movement Disorders: Isolated or predominant movement disorders (e.g., chorea, dystonia) can occur in specific etiologies (e.g., WNV, anti-basal ganglia antibodies).
  • Afebrile Encephalitis: Less common, but encephalitis can occur without fever, particularly in some autoimmune or chronic infections.
  • Brainstem Encephalitis: Can present with cranial nerve deficits, dysphagia, dysarthria, and respiratory compromise.

Physical Examination

• Inspection:
  • General Appearance: Level of consciousness (from alert to comatose), signs of distress, agitation, lethargy.
  • Skin: Rashes (e.g., maculopapular rash in enterovirus, vesicular rash in VZV, petechial rash in meningococcemia if meningoencephalitis). Bite marks (ticks, mosquitoes) or animal scratches.
  • Nuchal Rigidity: Resistance to passive neck flexion, indicating meningeal irritation (present in meningoencephalitis).
  • Pupils: Assess size, symmetry, and reactivity to light. Asymmetry or fixed pupils suggest increased ICP or focal brainstem involvement.
• Palpation:
  • Fontanelles (infants): Bulging fontanelle suggests increased ICP.
  • Lymphadenopathy: May be present in systemic infections.
• Special Tests:
  • Neurological Examination: Thorough assessment of mental status, cranial nerves, motor strength, sensation, coordination, reflexes.
    • Cranial Nerves: Palsies (e.g., facial droop, ophthalmoplegia), dysphagia, dysarthria.
    • Motor: Hemiparesis, paralysis, abnormal movements (tremor, myoclonus, ataxia, chorea).
    • Reflexes: Asymmetry, hyperreflexia, Babinski sign.
  • Meningeal Signs:
    • Kernig's Sign: Pain and resistance when extending the knee with the hip flexed to 90 degrees.
    • Brudzinski's Sign: Involuntary flexion of the hips and knees when the neck is passively flexed.
  • Fundoscopy: Check for papilledema, which is a late sign of increased ICP. May also reveal choroiditis (CMV).

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and Progression: Acute vs. subacute, sudden vs. gradual, pattern of symptom evolution.
  • Preceding Illnesses: Recent viral illness, rash, upper respiratory infection, gastroenteritis.
  • Epidemiological Exposure:
    • Travel history: To endemic areas for arboviruses (e.g., Asia for JE, Africa for TBE, WNV regions).
    • Animal contact: Bites, scratches, exposure to bats/mammals (rabies).
    • Insect exposure: Mosquito or tick bites.
    • Immunization status: Against measles, mumps, rubella, JE, TBE.
    • Contact with ill individuals: Especially for highly contagious infections.
  • Immunocompromised Status: HIV, organ transplant, cancer, immunosuppressive medications.
  • Comorbidities: Autoimmune diseases, malignancy.
  • Medications: Recent changes, new drugs, illicit drug use.
  • Psychiatric History: Relevant for differentiating psychiatric conditions from encephalitis.
• Red Flags:
  • Rapid decline in consciousness.
  • New-onset seizures, especially status epilepticus.
  • Focal neurological deficits.
  • Signs of increased intracranial pressure (e.g., vomiting, severe headache, pupillary changes).
  • Evidence of brainstem dysfunction.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC) with differential: Leukocytosis is common but non-specific.
  • Inflammatory Markers: Erythrocyte Sedimentation Rate (ESR), C-reactive protein (CRP) - usually elevated but non-specific.
  • Electrolytes, Renal and Liver Function Tests: Baseline assessment, rule out metabolic causes, monitor for SIADH (hyponatremia).
  • Blood Glucose: Rule out hypoglycemia or hyperglycemia as causes of altered mental status.
  • Blood Cultures: At least two sets, to rule out bacteremia or bacterial meningitis.
  • Lumbar Puncture (LP) for Cerebrospinal Fluid (CSF) Analysis: Crucial and typically mandatory unless contraindicated (e.g., signs of impending herniation or significant coagulopathy).
    • CSF cell count and differential: Typically lymphocytic pleocytosis (5-500 cells/µL, predominantly lymphocytes) in viral encephalitis. Neutrophilic pleocytosis can occur early in viral encephalitis, in bacterial, or partially treated bacterial.
    • CSF protein: Mild to moderately elevated (50-200 mg/dL).
    • CSF glucose: Normal (60-80% of blood glucose), or mildly decreased in some viral (mumps) or bacterial/fungal causes.
    • CSF Gram stain and bacterial culture: To rule out bacterial meningitis.
    • CSF PCR (Polymerase Chain Reaction): For common viral etiologies, especially HSV-1, HSV-2, VZV, enterovirus, West Nile virus, JE virus, CMV, EBV, HHV-6. This is the most important diagnostic test for viral encephalitis.
    • CSF Cryptococcal antigen: If immunocompromised or suspect fungal etiology.
• Confirmatory:
  • Specific CSF/Serum Serologies: IgM antibodies against arboviruses (e.g., WNV, JE) in CSF and/or serum. Paired acute and convalescent IgG titers.
  • CSF Oligoclonal Bands and IgG Index: May be elevated in autoimmune or demyelinating conditions.
  • Autoimmune Encephalitis Panel: CSF and serum antibodies for specific neuronal surface antigens (e.g., anti-NMDA receptor, anti-LGI1, anti-CASPR2, anti-GABA-B receptor, anti-AMPAR) if autoimmune etiology is suspected.
  • Brain Biopsy: Rarely performed, reserved for cases with persistent diagnostic uncertainty after comprehensive workup, particularly if treatable causes are suspected (e.g., focal lesions in immunocompromised, progressive decline, atypical imaging). High risk, only considered if diagnosis impacts treatment.
• Monitoring:
  • Serial neurological exams.
  • Repeat imaging (MRI) if clinical worsening or to monitor treatment response.
  • Repeat CSF analysis or specific pathogen testing if initial results are inconclusive or if clinical course is atypical.
  • EEG monitoring for seizure activity.

Imaging

• Recommended:
  • Magnetic Resonance Imaging (MRI) of the Brain with and without Contrast: Preferred imaging modality.
    • Findings: Can show characteristic patterns that suggest specific etiologies.
      • HSV-1 Encephalitis: T2-FLAIR hyperintensity and diffusion restriction, often in the medial temporal lobes, insular cortex, and cingulate gyrus, with occasional hemorrhagic changes.
      • WNV Encephalitis: T2-FLAIR hyperintensities in the basal ganglia, thalamus, brainstem, or cerebellum.
      • Acute Disseminated Encephalomyelitis (ADEM): Multifocal, asymmetric T2-FLAIR hyperintensities in white matter (often large and patchy).
      • Autoimmune Encephalitis: Can be normal, or show non-specific T2-FLAIR hyperintensities in medial temporal lobes or other limbic structures.
      • Other findings: Edema, mass effect, hydrocephalus, leptomeningeal enhancement (suggests meningeal involvement).
  • Computed Tomography (CT) Scan of the Brain with Contrast:
    • Role: Primarily used as an initial screening tool in the emergency setting to rule out other acute pathologies (hemorrhage, large mass, hydrocephalus) before lumbar puncture, especially if there are signs of increased ICP.
    • Limitations: Less sensitive than MRI for detecting early inflammatory changes in the brain parenchyma and often appears normal in early encephalitis.
• Advanced:
  • Diffusion-Weighted Imaging (DWI): Highly sensitive for detecting cytotoxic edema associated with acute inflammation and ischemia.
  • Magnetic Resonance Angiography/Venography (MRA/MRV): If vasculitis or venous thrombosis is suspected.
  • Positron Emission Tomography (PET) Scan (FDG-PET): May reveal patterns of hypermetabolism or hypometabolism that can aid in differentiating autoimmune from infectious encephalitis, or identifying paraneoplastic causes.

Management

Acute Management

• Immediate (First-Hour Interventions):
  • Airway, Breathing, Circulation (ABC) Stabilization: Assess and secure airway (intubation if GCS < 8 or respiratory compromise), ensure adequate ventilation and oxygenation. Establish IV access.
  • Initiate Empiric Therapy:
    • Antiviral: Start IV acyclovir (10 mg/kg IV every 8 hours, infused over 1 hour) immediately, without waiting for diagnostic test results, for any suspected viral encephalitis (especially to cover HSV-1, VZV). This is time-sensitive.
    • Antibacterial: Administer empiric broad-spectrum IV antibiotics (e.g., ceftriaxone 2 g IV every 12 hours + vancomycin 15 mg/kg IV every 8-12 hours) if bacterial meningitis/meningoencephalitis cannot be definitively excluded, particularly while awaiting CSF results. Consider ampicillin if Listeria is a concern (age >50, immunocompromised).
  • Manage Seizures: If present, administer IV benzodiazepines (e.g., lorazepam 2-4 mg IV) followed by loading doses of antiepileptic drugs (e.g., fosphenytoin, levetiracetam) for ongoing seizures or status epilepticus.
  • Manage Increased Intracranial Pressure (ICP):
    • Elevate head of bed to 30 degrees.
    • Avoid hyperthermia and hypercapnia.
    • Consider hyperosmolar therapy (e.g., mannitol 0.25-1 g/kg IV or hypertonic saline 3% IV) if signs of impending herniation or severe edema are present.
    • Emergent neurosurgical consultation for hydrocephalus or mass effect.
• Stabilization (Early Management Priorities):
  • Monitoring: Continuous cardiac, respiratory, and neurological monitoring in an ICU setting.
  • Fluid and Electrolyte Management: Strict intake and output, monitor for SIADH (hyponatremia). Correct electrolyte imbalances cautiously.
  • Fever Management: Antipyretics (acetaminophen, NSAIDs) to reduce metabolic demand and discomfort.
  • Nutritional Support: May require nasogastric or orogastric feeding if prolonged altered mental status.
  • Deep Vein Thrombosis (DVT) Prophylaxis: Heparin or enoxaparin if mobility is impaired.
  • Gastric Stress Ulcer Prophylaxis: Proton pump inhibitors or H2 blockers.
• Emergency (Crisis Management):
  • Refractory Status Epilepticus: May require continuous EEG monitoring, escalating antiepileptic therapy, or even induced coma with anesthetics (e.g., propofol, midazolam).
  • Cerebral Herniation: Immediate aggressive ICP management, potentially requiring decompressive craniectomy.
  • Cardiovascular Collapse/Shock: Address underlying cause, aggressive fluid resuscitation, vasopressors.

Chronic Management

• Pharmacological:
  • Targeted Antiviral Therapy:
    • HSV/VZV: IV acyclovir 10 mg/kg q8h for 14-21 days. Longer durations may be considered for severe or immunocompromised cases.
    • CMV: Ganciclovir 5 mg/kg IV q12h or Foscarnet 90 mg/kg IV q12h.
    • Other viruses: No specific antiviral for most arboviruses; treatment is supportive.
  • Antibiotics: Discontinue empiric antibiotics once bacterial meningitis/encephalitis is ruled out. If bacterial, tailor to culture sensitivities for appropriate duration.
  • Corticosteroids:
    • Autoimmune Encephalitis: High-dose IV methylprednisolone (1 g IV daily for 3-5 days) is first-line.
    • Infectious Encephalitis: Generally not recommended unless specific indications (e.g., ADEM, or severe cerebral edema with clear evidence of immune-mediated damage, though this is controversial and requires careful consideration). Can worsen viral replication in some cases.
  • Immunomodulatory Therapies (for Autoimmune Encephalitis):
    • First-line: IVIg (0.4 g/kg daily for 5 days) or plasma exchange (PLEX, 5-7 sessions over 7-10 days) after corticosteroids.
    • Second-line: Rituximab, cyclophosphamide for refractory cases or specific types.
  • Antiepileptic Drugs (AEDs): Continue if seizures occurred, long-term depending on seizure control and EEG findings.
  • Symptomatic Management: Antipyretics, analgesics, antiemetics.
• Non-pharmacological:
  • Rehabilitation: Early and aggressive physical, occupational, and speech therapy to maximize functional recovery. Neuropsychological rehabilitation for cognitive deficits.
  • Nutritional Support: Continue as needed.
  • Psychological Support: For patients and families dealing with neurological deficits and potential psychiatric sequelae (depression, anxiety).
  • Social Work: Assistance with long-term care planning and resources.
• Monitoring:
  • Neurological follow-up: Regular assessment of cognitive function, motor skills, and behavior.
  • Neuroimaging: Repeat MRI if clinical course is not improving or to assess for complications.
  • EEG: For monitoring seizure activity and guiding AED management.
  • Neuropsychological Testing: To quantify cognitive deficits and guide rehabilitation strategies.
  • Screening for underlying malignancy: In autoimmune encephalitis (especially paraneoplastic syndromes).

Treatment Algorithms

• First-Line:
  1. ABC Stabilization.
  2. Empiric IV Acyclovir (10 mg/kg q8h) for all suspected encephalitis.
  3. Empiric IV Broad-spectrum Antibiotics (e.g., ceftriaxone + vancomycin, +/- ampicillin) if bacterial meningitis/encephalitis cannot be ruled out.
  4. Seizure management and ICP management as needed.
  5. Diagnostic workup (LP, MRI, blood tests) performed urgently after empiric therapy initiated.
• Second-Line (Based on Etiology Confirmation):
  • HSV/VZV: Continue IV Acyclovir for 14-21 days.
  • CMV: Switch to IV Ganciclovir or Foscarnet.
  • Bacterial: Tailor antibiotics based on culture & sensitivity.
  • Fungal: Specific antifungal agents (e.g., amphotericin B, fluconazole).
  • Parasitic: Antiparasitic agents (e.g., albendazole, pyrimethamine/sulfadiazine).
  • Autoimmune: Stop antivirals/antibiotics, start high-dose IV methylprednisolone, followed by IVIg or PLEX. Search for underlying malignancy.
  • Undetermined: Continue acyclovir for full course. Consider expert consultation, repeat workup, or brain biopsy in selected cases.
• Refractory Cases:
  • Refractory seizures: Consider alternative AEDs, continuous EEG, anesthetics, vagal nerve stimulator.
  • Refractory autoimmune encephalitis: Second-line immunosuppressants (rituximab, cyclophosphamide), corticosteroids for longer duration, or combination therapies.
  • Persistent inflammation/edema: Consider cautious use of corticosteroids if non-infectious cause likely.
  • Diagnostic uncertainty: Re-evaluate diagnosis, consider brain biopsy in highly selected cases.

Complications

• Common:
  • Seizures: Including new-onset epilepsy.
  • Hyponatremia: Often due to SIADH.
  • Cognitive deficits: Memory impairment, executive dysfunction, reduced processing speed.
  • Behavioral and psychiatric changes: Irritability, anxiety, depression, psychosis, personality changes.
  • Motor deficits: Weakness, ataxia, abnormal movements.
  • Speech and language deficits: Aphasia, dysarthria.
• Serious:
  • Status epilepticus: Life-threatening, requiring aggressive management.
  • Increased Intracranial Pressure (ICP) with herniation: Can lead to brain damage and death.
  • Hydrocephalus: May require ventriculostomy or shunting.
  • Severe autonomic dysfunction: Blood pressure lability, cardiac arrhythmias.
  • Respiratory failure: Due to brainstem involvement or severe altered mental status.
  • Coma and Death.
• Long-term:
  • Permanent neurological deficits: Varying degrees of cognitive, motor, and sensory impairment.
  • Epilepsy: Chronic seizure disorder requiring long-term AEDs.
  • Neurodevelopmental delay (in children).
  • Persistent psychiatric sequelae: Chronic depression, anxiety disorders, post-traumatic stress disorder, personality changes.
  • Fatigue and sleep disturbances.
  • Reduced quality of life and functional independence.

Prognosis

• Factors:
  • Etiology: Varies significantly. Untreated HSV encephalitis has a mortality rate of 70%, reduced to 20-30% with acyclovir. WNV encephalitis mortality is 10-15%. Autoimmune encephalitis generally has better outcomes with early immunotherapy.
  • Age: Extremes of age (infants and elderly) have worse prognosis.
  • Severity at presentation: Lower GCS score, presence of status epilepticus, significant focal neurological deficits, and signs of increased ICP are associated with worse outcomes.
  • Rapidity of Diagnosis and Treatment: Prompt initiation of specific therapy (e.g., acyclovir for HSV) is critical for improving outcomes.
  • Extent of Brain Damage: As seen on imaging (e.g., extensive temporal lobe damage in HSV).
  • Immunological Status: Immunocompromised patients often have more severe disease.
• Survival: Overall mortality for AES ranges from 5-20%, but can be higher for specific etiologies or in high-risk groups.
• Quality of Life: A significant proportion of survivors experience long-term neurological and neuropsychological sequelae, leading to reduced quality of life, impaired functional independence, and need for ongoing rehabilitation and support. This can include cognitive impairment, epilepsy, motor deficits, and psychiatric disorders.

Prevention

• Primary (Preventing Initial Occurrence):
  • Vaccination:
    • Japanese Encephalitis Vaccine: For travelers to or residents of endemic areas.
    • MMR, Varicella (VZV), Polio Vaccines: Part of routine childhood immunization schedules.
    • Tick-borne Encephalitis Vaccine: For individuals in endemic regions of Europe/Asia.
    • Rabies Vaccine: For high-risk individuals (vets, animal handlers, travelers).
    • Influenza Vaccine: Annual vaccination can prevent influenza-associated encephalitis.
  • Vector Control:
    • Mosquitoes: Use insect repellents (DEET, picaridin), wear protective clothing, eliminate standing water, use screens on windows/doors, mosquito nets.
    • Ticks: Avoid tick-infested areas, check for and remove ticks promptly.
  • Hygiene: Handwashing, safe food and water practices.
  • Avoid Contact with Wild Animals: Especially for rabies prevention.
• Secondary (Early Detection and Intervention):
  • Public Health Surveillance: Monitoring for outbreaks of arboviral diseases.
  • High Index of Suspicion: Clinicians should maintain a high index of suspicion for AES in patients presenting with fever and altered mental status, and initiate empiric treatment promptly.
  • Rapid Diagnostic Testing: Availability of rapid PCR testing for common viral causes to enable targeted therapy.
• Tertiary (Preventing Complications):
  • Early Rehabilitation: Aggressive physical, occupational, speech, and cognitive therapy to minimize long-term disability.
  • Long-term Follow-up: Monitoring for chronic neurological and psychiatric sequelae, and managing them proactively.
  • Antiepileptic medications: For seizure prevention and control.

Special Populations

• Pediatric:
  • Etiologies: Enteroviruses, HHV-6, measles, mumps are relatively more common. HSV-2 can cause neonatal encephalitis.
  • Presentation: May be non-specific in infants (irritability, poor feeding, bulging fontanelle, lethargy, high-pitched cry).
  • Dosages: Medication dosages (e.g., acyclovir) must be weight-adjusted.
  • Prognosis: Higher risk of long-term neurodevelopmental deficits and epilepsy due to ongoing brain development.
  • Imaging: MRI may show diffuse involvement rather than focal.
• Geriatric:
  • Etiologies: Higher risk for WNV, Listeria monocytogenes, and reactivated VZV.
  • Presentation: Atypical presentation more common (e.g., subtle mental status changes, delayed fever, predominant lethargy). May have pre-existing cognitive decline, making diagnosis challenging.
  • Comorbidities: Often have multiple comorbidities, complicating management and increasing risk of adverse drug reactions.
  • Prognosis: Higher mortality and poorer functional outcomes due to physiological reserve and comorbidities.
• Pregnancy:
  • Considerations: Balancing maternal and fetal health. Avoidance of potentially teratogenic medications if possible, but life-saving therapies for encephalitis take precedence.
  • HSV Encephalitis: Acyclovir is generally considered safe in pregnancy. Neonatal HSV can occur if HSV-2 encephalitis in mother.
  • Diagnosis: Imaging (MRI) is preferred over CT to avoid radiation exposure to the fetus. Lumbar puncture is safe.
  • Treatment: Empiric acyclovir is crucial.
• Comorbidities (Immunocompromised Patients):
  • Broader Differential: Consider opportunistic infections (CMV, EBV, JC virus (PML), Toxoplasma, Cryptococcus, other fungi).
  • Presentation: May be atypical, less pronounced inflammatory response (e.g., lower fever, less pleocytosis in CSF).
  • Diagnosis: Require more extensive diagnostic workup, including specific PCRs and cultures for opportunistic pathogens. Brain biopsy may be considered earlier.
  • Treatment: Requires targeted therapy against specific opportunistic pathogens, in addition to empiric acyclovir. May also require adjustment of immunosuppressive therapy.
  • Prognosis: Generally worse due to underlying immune deficiency and severity of infections.

Clinical Pearls

• Diagnostic:
  • "Time is Brain": Any patient presenting with acute fever, headache, and altered mental status/seizures must be presumed to have encephalitis, specifically HSV encephalitis, until proven otherwise.
  • Don't Delay Acyclovir: Initiate empiric IV acyclovir immediately. Do NOT wait for MRI or LP results if encephalitis is suspected, as delay drastically worsens prognosis for HSV encephalitis.
  • LP is King: Lumbar puncture with CSF analysis (cell count, protein, glucose, Gram stain, bacterial culture, and especially viral PCRs for HSV-1, HSV-2, VZV, enterovirus, WNV, JE) is the cornerstone of diagnosis.
  • MRI is Superior: MRI with contrast is the imaging modality of choice for encephalitis, providing more detail and characteristic findings than CT.
  • Think Autoimmune: If the initial infectious workup is negative, especially with prominent psychiatric symptoms, movement disorders, or refractory seizures, consider autoimmune encephalitis and test for autoantibodies in CSF and serum.
• Treatment:
  • Acyclovir Duration: If HSV encephalitis is confirmed or highly suspected, continue IV acyclovir for a full 14-21 days. Do not stop early unless an alternative diagnosis is definitively established.
  • Empiric Antibiotics: While awaiting CSF results, also consider empiric broad-spectrum antibiotics, especially if the patient is severely ill or meningeal signs are prominent, to cover for bacterial meningoencephalitis.
  • Supportive Care: Aggressive supportive care (airway management, seizure control, ICP management, fluid/electrolyte balance) is crucial alongside targeted therapy.
• Pitfalls:
  • Delaying Acyclovir: The most critical mistake. Every hour of delay increases morbidity and mortality in HSV encephalitis.
  • Inadequate Workup: Not performing an LP or comprehensive CSF PCR panel.
  • Stopping Acyclovir Prematurely: Discontinuing acyclovir after a "negative" initial CSF PCR if clinical suspicion remains high (false negatives can occur, especially early). Repeat LP or consider brain biopsy if diagnosis remains elusive.
  • Missing Autoimmune Causes: Focusing solely on infectious causes and overlooking treatable autoimmune encephalitis.
  • Overlooking Meningitis: Confusing encephalitis with meningitis alone (encephalitis requires altered brain function, not just meningeal inflammation).

Recent Updates

• Guidelines:
  • Infectious Diseases Society of America (IDSA): Updated guidelines for the diagnosis and management of infectious encephalitis provide detailed recommendations on diagnostic testing, empiric and pathogen-specific treatments.
  • World Health Organization (WHO): Continues to update surveillance and management guidelines for specific arboviral encephalitides (e.g., JE, WNV, Zika) relevant to endemic regions.
  • European Federation of Neurological Societies (EFNS): Provides consensus guidelines on autoimmune encephalitis.
• Evidence:
  • Expanding Spectrum of Autoimmune Encephalitis: Continuous discovery of new autoantibodies and clinical syndromes (e.g., recognition of encephalitis associated with LGI1, CASPR2, GABAb-R antibodies) leading to improved diagnosis and treatment.
  • Improved Diagnostic Tools: Enhanced sensitivity and speed of multiplex PCR panels for CSF analysis, and increasing availability of comprehensive autoimmune antibody panels. Next-generation sequencing for pathogen identification in complex cases is emerging.
  • Prognostic Markers: Research into biomarkers (e.g., neurofilament light chain) for predicting severity and long-term outcomes is ongoing.
• Controversies:
  • Role of Corticosteroids in Infectious Encephalitis: Generally not recommended due to potential harm, but some limited evidence suggests benefit in specific infectious causes with significant inflammatory or immune-mediated components (e.g., ADEM, or severe cerebral edema in VZV), remaining an area of debate and individualized decision-making.
  • Optimal Duration of Antiviral Therapy: While 14-21 days is standard for HSV, specific situations (e.g., immunocompromised, recurrent disease) might warrant longer courses, which is still under investigation.
  • Management of Encephalitis of Unknown Etiology: The optimal approach to cases where a pathogen cannot be identified despite extensive workup remains challenging, balancing risks of empirical treatments against the benefits of specific therapy.

Key References

• Guidelines:
  • Infectious Diseases Society of America (IDSA) Guidelines for the Diagnosis and Management of Encephalitis. Clinical Infectious Diseases, 2008; 47(3): 303-27. (Note: While 2008, still a foundational reference; updates are incremental or disease-specific).
  • European Federation of Neurological Societies/European Academy of Neurology (EFNS/EAN) guidelines for the diagnosis and management of autoimmune encephalitis. European Journal of Neurology, 2021; 28(12): 4125-4148.
  • World Health Organization (WHO) initiatives and guidelines on surveillance and management of arboviral diseases (e.g., Japanese encephalitis).
• Studies:
  • Studer R, et al. Global incidence of encephalitis: a systematic review and meta-analysis. Lancet Global Health, 2021; 9(4): e409-e417.
  • Bradshaw MJ, et al. Aetiologies of encephalitis: an update. Practical Neurology, 2022; 22(3): 199-209.
  • Dalmau J, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurology, 2011; 10(1): 63-74.
• Reviews:
  • Chaudhuri A, Kennedy PGE. Diagnosis and treatment of viral encephalitis. Postgraduate Medical Journal, 2002; 78(916): 57-63.
  • Lancaster E. The Diagnosis and Treatment of Autoimmune Encephalitis. Journal of Clinical Neurology, 2016; 12(1): 1-13.
  • Granerod J, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infectious Diseases, 2010; 10(12): 835-44.